biotech / news / / Reuters
sacituzumab tirumotecan, or sac-TMT, showed a statistically significant and clinically meaningful improvement in both overall survival and how long patients lived before their disease worsened.
sac-TMT achieved statistically significant improvement in survival versus chemotherapy in endometrial cancer trial.
KEY POINTS
- The trial included 776 patients with advanced or recurrent endometrial cancer pretreated with platinum and immunotherapy.
- sac-TMT targets tumor cells by binding to the TROP2 protein, delivering chemotherapy directly.
- FDA has selected sac-TMT for its National Priority Voucher program, potentially expediting review to as little as one month.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →